Stock Watch: Biotech’s Commercial Laggards Drag On Sector
Biotech Companies Can Remain Unprofitable Years After Product Launches
Executive Summary
Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.